Drug-drug Interaction Study of CHF5993 With Cimetidine
Status:
Completed
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the pharmacokinetic interaction when CHF5993
(pressurized metered-dose inhaler (pMDI) is administered with Cimetidine (probe inhibitor of
the organic cation transport in the kidneys), by comparing the systemic exposure (AUC0-t) of
Glycopyrronium Bromide (GB), after a single dose of the fixed combination CHF 5993 pMDI
administered alone or at steady-state of Cimetidine